Janney Montgomery Scott Reaffirms Hold Rating for Supernus Pharmaceuticals, Inc. (SUPN)
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)‘s stock had its “hold” rating reissued by investment analysts at Janney Montgomery Scott in a research report issued on Wednesday. They currently have a $47.00 price target on the specialty pharmaceutical company’s stock. Janney Montgomery Scott’s price objective points to a potential upside of 27.89% from the company’s previous close.
SUPN has been the subject of a number of other research reports. BidaskClub cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $51.00 target price on shares of Supernus Pharmaceuticals in a research note on Friday, August 4th. Cowen and Company reiterated a “positive” rating and issued a $50.00 target price (up previously from $40.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, August 3rd. Stifel Nicolaus reiterated a “buy” rating and issued a $47.00 target price (up previously from $36.00) on shares of Supernus Pharmaceuticals in a research note on Tuesday, July 18th. Finally, Piper Jaffray Companies reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, August 4th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $48.29.
Supernus Pharmaceuticals (SUPN) traded down 3.42% during mid-day trading on Wednesday, reaching $36.75. The company had a trading volume of 2,357,784 shares. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of 18.54 and a beta of 1.30. The company’s 50 day moving average is $44.56 and its 200 day moving average is $37.95. Supernus Pharmaceuticals has a 52-week low of $17.25 and a 52-week high of $50.05.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.08. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The company had revenue of $75.83 million during the quarter, compared to analysts’ expectations of $68.54 million. Equities analysts predict that Supernus Pharmaceuticals will post $1.04 earnings per share for the current year.
In related news, CFO Gregory S. Patrick sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $47.60, for a total value of $2,380,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 3,735 shares of the business’s stock in a transaction that occurred on Wednesday, July 12th. The stock was sold at an average price of $44.90, for a total transaction of $167,701.50. Following the completion of the transaction, the vice president now owns 21,209 shares of the company’s stock, valued at approximately $952,284.10. The disclosure for this sale can be found here. Insiders sold a total of 160,000 shares of company stock valued at $7,505,574 in the last 90 days. 6.70% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of SUPN. BlackRock Inc. raised its position in Supernus Pharmaceuticals by 156,173.3% in the 1st quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock worth $209,595,000 after purchasing an additional 6,692,025 shares during the last quarter. Vanguard Group Inc. raised its position in Supernus Pharmaceuticals by 39.1% in the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after purchasing an additional 984,200 shares during the last quarter. Emerald Advisers Inc. PA bought a new position in Supernus Pharmaceuticals in the 2nd quarter worth approximately $21,474,000. Emerald Mutual Fund Advisers Trust bought a new position in Supernus Pharmaceuticals in the 2nd quarter worth approximately $17,553,000. Finally, Hodges Capital Management Inc. bought a new position in Supernus Pharmaceuticals in the 2nd quarter worth approximately $17,220,000. Hedge funds and other institutional investors own 95.38% of the company’s stock.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.